Qureator recently co-hosted its “Human-Based Technology for Toxicology Research” workshop with Physicians Committee for Responsible Medicine, held in conjunction with the Society of Toxicology (SOT 2026) Annual Meeting. The event welcomed global researchers for a facility tour and an immersive look at how microphysiological systems (MPS) are advancing human-relevant drug discovery.
Participants engaged in hands-on sessions featuring Qureator’s CurioChip platform. Led by company experts, these interactive modules explored liquid patterning, the automation of complex tissue models, and high-content 3D imaging of tissue-in-chips. These technologies represent a pivotal shift toward generating more accurate, human-centric data in safety assessment.
A highlight of the event was a panel discussion on the FDA Modernization Act 2.0 and New Approach Methodologies (NAMs). Co-hosted by the Physicians Committee for Responsible Medicine, the panel featured experts from GAP Solutions/NIH and Qureator’s leadership. The conversation underscored the growing momentum behind ethical, animal-free science.
By bridging the gap between innovative engineering and regulatory evolution, Qureator continues to lead the transition toward a human-based future for toxicology.